Miguel Servet University Hospital
Welcome,         Profile    Billing    Logout  
 2 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Anton, Antonio
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
40
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
03/25
08/29
Phenomenal, NCT03328884 / 2016-002689-30: Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients

Active, not recruiting
2
55
Europe
Irinotecan Hydrochloride, nal-IRI
MedSIR
Breast Cancer Metastatic
08/18
06/25
MiRaDoR, NCT05708235: A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Recruiting
2
1260
Europe
Giredestrant, GDC-9545, Abemaciclib, LY2835219, Inavolisib, GDC-0077
MedSIR
Breast Cancer
12/28
12/28
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Data from the GARNET study in solid tumor at ASCO GI 2020
Jan 2021 - Jan 2021: Data from the GARNET study in solid tumor at ASCO GI 2020
Checkmark Data from the GARNET study in recurrent or advanced endometrial cancer at ESMO 2020
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27

Download Options